JosephHulihanMD

Neurophysiology

Principal at Paradigm Consulting, LLC

Dr. Hulihan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 1987 - 1990
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1986 - 1987
Drexel University College of MedicineClass of 1986

PubMed

31 citations
Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate.
Stephen D. Silberstein, Hans-Christoph Diener, Richard B. Lipton, Peter J. Goadsby, David W. Dodick
Headache. 2008-07-01
37 citations
Association Between Treatment Progression, Disease Refractoriness, and Burden of Illness Among Hospitalized Patients With Status Epilepticus.
Elan L. Guterman, John P. Betjemann, Aimetti Alex, Justin W Li, Zheng Wang
JAMA Neurology. 2021-05-01
219 citations
Assessment of interrater and intrarater reliability of the Fahn–Tolosa–Marin Tremor Rating Scale in essential tremor
Mark Stacy, Rodger J. Elble, William G. Ondo, Shu Chen Wu, Joseph Hulihan
Movement Disorders. 2007-04-30

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline UpdateAugust 3rd, 2021
Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect ConferenceJanuary 6th, 2021
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)July 30th, 2020